Literature DB >> 19738415

Identification of HLA-A11-restricted CTL epitopes derived from HPV type 18 using DNA immunization.

Hsin-Wei Chen1, Chih-Hsiang Leng, Hsin-Yu Liu, Wen-Fang Cheng, Yu-Wen Chang, Pin-Yi Wu, Shu-Pei Lien, Tzu-Yi Huang, Sheng-Kuo Chiang, Min-Han Lin, Mi-Hua Tao, Pele Chong, Shih-Jen Liu.   

Abstract

Identification of the cytotoxic T lymphocyte (CTL) epitopes of tumor antigens is important for effective immunotherapy. We report that a combination of epitope prediction, enzyme-linked immunosorbent assay (ELISA)-based epitope-HLA complex formation, and DNA immunization methods can improve the efficiency and accuracy of CTL epitope studies. In this study, two HLA-A11-restricted epitopes derived from human papillomavirus (HPV)18 E6 oncoprotein were identified. HLA-A11-transgenic mice immunized with these epitopes could specifically induce interferon-gamma (IFNgamma) production, cytotoxicity and peptide/HLA-A11 tetramer binding in CD8(+) T-cells. To study intracellular processing of CTL epitopes, we constructed a DNA plasmid containing an endoplasmic reticulum (ER) targeting sequence as well as the HPV18 E6 and E7 genes (pEK/HPV18E6E7). CTL responses against peptide-pulsed T2/A11 cells could be detected after immunizing HLA-A11-transgenic mice with pEK/HPV18E6E7. Furthermore, the identified peptides could stimulate T-cells to secrete IFNgamma from HPV18-infected patients. Our results demonstrate that the antigenic E6 peptides derived from HPV18 are potential candidates for the treatment of HPV 18-associated tumors in HLA-A11(+) populations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19738415     DOI: 10.4161/cbt.8.21.9732

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  8 in total

1.  Generation of human MHC (HLA-A11/DR1) transgenic mice for vaccine evaluation.

Authors:  Yang Zeng; Tongtong Gao; Guangyu Zhao; Yuting Jiang; Yi Yang; Hong Yu; Zhihua Kou; Yuchun Lone; Shihui Sun; Yusen Zhou
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model.

Authors:  Ying Ma; Andrew Yang; Shiwen Peng; Jin Qiu; Emily Farmer; Chien-Fu Hung; T-C Wu
Journal:  Vaccine       Date:  2017-06-07       Impact factor: 3.641

3.  Endoplasmic reticulum-targeting sequence enhanced the cellular immunity of a tumor-associated antigen L6-based DNA vaccine.

Authors:  Yuh-Pyng Sher; Su-I Lin; Kit Man Chai; I-Hua Chen; Shih-Jen Liu
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

4.  T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.

Authors:  Paul K S Chan; Shih-Jen Liu; T H Cheung; Winnie Yeo; S M Ngai; Jo L K Cheung; Pele Chong; Stephen Man
Journal:  Clin Vaccine Immunol       Date:  2010-07-28

5.  A HLA-A2-restricted CTL epitope induces anti-tumor effects against human lung cancer in mouse xenograft model.

Authors:  Yuh-Pyng Sher; Su-I Lin; I-Hua Chen; Hsin-Yu Liu; Chen-Yuan Lin; I-Ping Chiang; Steve Roffler; Hsin-Wei Chen; Shih-Jen Liu
Journal:  Oncotarget       Date:  2016-01-05

Review 6.  Therapeutic DNA Vaccines against HPV-Related Malignancies: Promising Leads from Clinical Trials.

Authors:  Jianming Tang; Mingzhu Li; Chao Zhao; Danhua Shen; Lei Liu; Xiujun Zhang; Lihui Wei
Journal:  Viruses       Date:  2022-01-25       Impact factor: 5.048

7.  Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice.

Authors:  Shiwen Peng; Deyin Xing; Louise Ferrall; Ya-Chea Tsai; Chien-Fu Hung; T-C Wu
Journal:  J Biomed Sci       Date:  2022-10-12       Impact factor: 12.771

8.  Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide.

Authors:  Kuan-Yin Shen; Ying-Chyi Song; I-Hua Chen; Pele Chong; Shih-Jen Liu
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.